Empowered Patient Podcast Facilitating Innovation and Bringing Operational Efficiencies to Drug Development and Commercialization with Anupam Girdhar Ascential Technologies
Anupam Girdhar, CEO of medical and life sciences at Ascential Technologies, provides contract manufacturing services primarily to Fortune 100 companies, focusing on solving the most complex drug development and manufacturing challenges. By aligning with customers early on to understand the scope and risks of a project, Ascential can save time and money when bringing drugs and medical devices to market. At the same time, Anupam reminds us that innovation and inefficiency are part of the process for those trying to explore the unknown.
Anupam explains, "This is where I enjoy some of the interactions we have with our customers, because if you think about fundamentally what the industry is trying to do, it is about democratizing care to the patients. We are all in the business of serving them and improving patients’ lives. A lot of these challenges that we encounter are mostly in the areas of, how do we provide access to more and more patients, as well as, how do we lower the cost fundamentally for both the companies and consumers? That’s where the challenges we encounter are mostly."
"You’ve probably heard of so many projects that were thought of as game-changing and did not do much in the world. I know when customers come to us, everybody thinks their idea is the best, and I don’t blame that. That should be the attitude, and that’s how big things happen, but they cannot close their eyes to the learning. I mean, there are times when they completely overlook what it takes to fully scale something. There are technologies that are just unfeasible, where we will try to do something that is just against what is possible based on the laws of time or how much cost it takes to get there. There are still areas where we look back into our own backgrounds and then go ahead and incorporate those in the design."
"An example is our proteomics board. In the past, and even in my experience, we’ve had more focus on genomics, and there are companies that were focused on proteomics. Still, now we have enough technology to combine things and learn multi-omic processes and so on. That just gives me so much joy to be able to now integrate things that we could not do five to ten years ago."
#AscentialTechnologies #AscentialMedicalLifeSciences #Ascential #ContractManufacturing #ManufacturingAutomation #CellTherapy #MedicalDevice